Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance
In antibody therapy, researchers create custom-made antibodies that bind to cells such as tumor cells, flagging them for destruction by the immune system. It’s a powerful technology — but for some types of cells, there’s nowhere to attach an antibody. Solu Therapeutics literally bridges this gap using proprietary molecules called Cytotoxicity Targeting Chimeras (CyTaCs) that attach to target cells on one end and antibodies on the other. The company’s first clinical candidate will target blood cancers.
Mapping the brain-body axis to achieve proper immune balance
Using AI to speed through the last mile of drug discovery
Finding precisely tuned viral vectors for gene therapy in CNS disorders
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors